| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy Complications | 21 | 2021 | 105 | 5.550 |
Why?
|
| Lupus Erythematosus, Systemic | 30 | 2021 | 986 | 4.120 |
Why?
|
| Antirheumatic Agents | 17 | 2018 | 56 | 3.800 |
Why?
|
| Rheumatic Diseases | 10 | 2018 | 33 | 3.580 |
Why?
|
| Arthritis, Rheumatoid | 16 | 2018 | 132 | 3.400 |
Why?
|
| Immunosuppressive Agents | 11 | 2020 | 140 | 2.990 |
Why?
|
| Herpes Zoster | 8 | 2017 | 20 | 2.880 |
Why?
|
| Pregnancy Outcome | 15 | 2021 | 128 | 2.170 |
Why?
|
| Herpes Zoster Vaccine | 5 | 2017 | 10 | 2.120 |
Why?
|
| Autoimmune Diseases | 7 | 2017 | 162 | 1.660 |
Why?
|
| Pregnancy | 27 | 2021 | 1130 | 1.570 |
Why?
|
| Scleroderma, Systemic | 5 | 2012 | 29 | 1.310 |
Why?
|
| Female | 62 | 2021 | 14462 | 1.270 |
Why?
|
| Humans | 78 | 2021 | 26842 | 1.220 |
Why?
|
| Hospitalization | 6 | 2017 | 189 | 1.140 |
Why?
|
| Maternal Exposure | 3 | 2018 | 16 | 1.130 |
Why?
|
| Lupus Nephritis | 3 | 2019 | 99 | 1.030 |
Why?
|
| Primary Ovarian Insufficiency | 2 | 2021 | 6 | 0.920 |
Why?
|
| Adult | 36 | 2020 | 7382 | 0.850 |
Why?
|
| Autoantibodies | 4 | 2020 | 466 | 0.810 |
Why?
|
| Menopause, Premature | 1 | 2020 | 3 | 0.740 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 38 | 0.720 |
Why?
|
| Reproductive Health | 2 | 2018 | 5 | 0.720 |
Why?
|
| Ovary | 1 | 2020 | 69 | 0.710 |
Why?
|
| Lactation | 3 | 2021 | 55 | 0.640 |
Why?
|
| Middle Aged | 27 | 2020 | 6818 | 0.630 |
Why?
|
| Drug Labeling | 1 | 2018 | 4 | 0.620 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 43 | 0.610 |
Why?
|
| Running | 2 | 2008 | 39 | 0.610 |
Why?
|
| Abatacept | 2 | 2015 | 5 | 0.600 |
Why?
|
| Risk Factors | 14 | 2021 | 2010 | 0.600 |
Why?
|
| Certolizumab Pegol | 1 | 2017 | 2 | 0.600 |
Why?
|
| Gene Expression | 2 | 2020 | 406 | 0.590 |
Why?
|
| Herpesvirus 3, Human | 2 | 2017 | 12 | 0.590 |
Why?
|
| United States | 12 | 2018 | 2031 | 0.590 |
Why?
|
| Fetal Blood | 1 | 2017 | 37 | 0.580 |
Why?
|
| Abnormalities, Drug-Induced | 3 | 2014 | 10 | 0.580 |
Why?
|
| Vaccination | 2 | 2021 | 167 | 0.570 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2017 | 35 | 0.550 |
Why?
|
| Patient Participation | 3 | 2020 | 52 | 0.540 |
Why?
|
| Severity of Illness Index | 9 | 2018 | 446 | 0.520 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2015 | 243 | 0.520 |
Why?
|
| Scleroderma, Diffuse | 1 | 2015 | 2 | 0.510 |
Why?
|
| Skin Neoplasms | 2 | 2008 | 128 | 0.510 |
Why?
|
| CD28 Antigens | 1 | 2015 | 11 | 0.500 |
Why?
|
| Antibodies, Monoclonal | 4 | 2011 | 316 | 0.500 |
Why?
|
| Papillomavirus Infections | 1 | 2017 | 137 | 0.500 |
Why?
|
| Male | 28 | 2020 | 12871 | 0.480 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2011 | 41 | 0.470 |
Why?
|
| Premature Birth | 2 | 2013 | 48 | 0.470 |
Why?
|
| Preconception Care | 2 | 2014 | 17 | 0.460 |
Why?
|
| Family Planning Services | 1 | 2014 | 5 | 0.460 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2017 | 277 | 0.460 |
Why?
|
| Fetal Growth Retardation | 2 | 2012 | 30 | 0.460 |
Why?
|
| Delivery, Obstetric | 3 | 2017 | 38 | 0.450 |
Why?
|
| Aged | 18 | 2020 | 5166 | 0.450 |
Why?
|
| Gastrointestinal Diseases | 1 | 2014 | 54 | 0.440 |
Why?
|
| Biological Products | 1 | 2014 | 60 | 0.430 |
Why?
|
| Physician-Patient Relations | 1 | 2014 | 112 | 0.410 |
Why?
|
| Incidence | 5 | 2016 | 545 | 0.400 |
Why?
|
| Disabled Persons | 1 | 2012 | 18 | 0.400 |
Why?
|
| Disability Evaluation | 3 | 2008 | 54 | 0.400 |
Why?
|
| Mixed Connective Tissue Disease | 2 | 2015 | 3 | 0.390 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 441 | 0.380 |
Why?
|
| Infant, Low Birth Weight | 1 | 2011 | 23 | 0.380 |
Why?
|
| Hypertension | 2 | 2012 | 304 | 0.370 |
Why?
|
| Remission, Spontaneous | 1 | 2010 | 8 | 0.360 |
Why?
|
| Longevity | 1 | 2012 | 129 | 0.360 |
Why?
|
| Health Behavior | 1 | 2012 | 153 | 0.350 |
Why?
|
| Antiphospholipid Syndrome | 2 | 2007 | 30 | 0.350 |
Why?
|
| Antibodies, Antinuclear | 4 | 2020 | 181 | 0.350 |
Why?
|
| Exercise | 2 | 2012 | 451 | 0.350 |
Why?
|
| Clinical Trials as Topic | 3 | 2020 | 205 | 0.350 |
Why?
|
| Lymphocyte Activation | 4 | 2020 | 204 | 0.340 |
Why?
|
| Self Disclosure | 1 | 2009 | 4 | 0.340 |
Why?
|
| Databases as Topic | 1 | 2009 | 21 | 0.340 |
Why?
|
| Epilepsy | 1 | 2009 | 32 | 0.340 |
Why?
|
| Arthritis | 1 | 2009 | 29 | 0.330 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 160 | 0.330 |
Why?
|
| Rheumatology | 2 | 2021 | 17 | 0.320 |
Why?
|
| Immunologic Factors | 4 | 2015 | 48 | 0.320 |
Why?
|
| Virus Latency | 1 | 2008 | 9 | 0.320 |
Why?
|
| Immunoglobulin G | 4 | 2014 | 266 | 0.320 |
Why?
|
| Multiple Sclerosis | 1 | 2009 | 80 | 0.310 |
Why?
|
| Virus Diseases | 1 | 2008 | 38 | 0.310 |
Why?
|
| Mortality | 1 | 2008 | 43 | 0.310 |
Why?
|
| Osteoarthritis, Knee | 1 | 2008 | 24 | 0.300 |
Why?
|
| Hypertension, Pulmonary | 1 | 2008 | 30 | 0.300 |
Why?
|
| Anemia, Sickle Cell | 1 | 2008 | 38 | 0.290 |
Why?
|
| Databases, Factual | 5 | 2018 | 250 | 0.290 |
Why?
|
| Infant, Newborn | 4 | 2018 | 844 | 0.290 |
Why?
|
| Hypertension, Malignant | 1 | 2007 | 3 | 0.290 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 910 | 0.290 |
Why?
|
| Hospital Mortality | 1 | 2007 | 146 | 0.280 |
Why?
|
| Melanoma | 1 | 2008 | 140 | 0.280 |
Why?
|
| Methotrexate | 2 | 2005 | 32 | 0.280 |
Why?
|
| Interferon-alpha | 3 | 2018 | 50 | 0.280 |
Why?
|
| Surveys and Questionnaires | 6 | 2018 | 918 | 0.280 |
Why?
|
| Dendritic Cells | 2 | 2018 | 142 | 0.260 |
Why?
|
| Research Design | 1 | 2007 | 174 | 0.260 |
Why?
|
| Prospective Studies | 3 | 2017 | 1216 | 0.250 |
Why?
|
| Opportunistic Infections | 2 | 2021 | 14 | 0.250 |
Why?
|
| Treatment Outcome | 5 | 2020 | 2264 | 0.250 |
Why?
|
| Multivariate Analysis | 4 | 2014 | 298 | 0.250 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2018 | 96 | 0.250 |
Why?
|
| Giant Cells | 1 | 2005 | 1 | 0.250 |
Why?
|
| Coronary Disease | 1 | 2005 | 118 | 0.250 |
Why?
|
| Myocarditis | 1 | 2005 | 16 | 0.240 |
Why?
|
| Registries | 3 | 2020 | 383 | 0.240 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 657 | 0.240 |
Why?
|
| Neoplasms | 2 | 2004 | 756 | 0.240 |
Why?
|
| Natural Killer T-Cells | 2 | 2016 | 54 | 0.240 |
Why?
|
| Aging | 1 | 2012 | 945 | 0.230 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2004 | 8 | 0.230 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2007 | 216 | 0.230 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2018 | 110 | 0.230 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2005 | 152 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 233 | 0.220 |
Why?
|
| Time Factors | 3 | 2020 | 1562 | 0.220 |
Why?
|
| Risk Assessment | 4 | 2021 | 586 | 0.210 |
Why?
|
| Echocardiography | 2 | 2018 | 107 | 0.210 |
Why?
|
| Adolescent | 5 | 2017 | 2957 | 0.210 |
Why?
|
| Aged, 80 and over | 5 | 2014 | 1926 | 0.210 |
Why?
|
| Longitudinal Studies | 4 | 2014 | 400 | 0.210 |
Why?
|
| Young Adult | 6 | 2017 | 2582 | 0.210 |
Why?
|
| Biomarkers | 4 | 2020 | 733 | 0.210 |
Why?
|
| Rituximab | 3 | 2011 | 60 | 0.200 |
Why?
|
| Length of Stay | 3 | 2008 | 215 | 0.200 |
Why?
|
| B-Lymphocytes | 2 | 2018 | 276 | 0.200 |
Why?
|
| California | 3 | 2007 | 63 | 0.200 |
Why?
|
| Diagnosis, Differential | 4 | 2007 | 367 | 0.190 |
Why?
|
| Pre-Eclampsia | 3 | 2006 | 48 | 0.190 |
Why?
|
| Infant | 2 | 2017 | 957 | 0.190 |
Why?
|
| Retrospective Studies | 6 | 2018 | 2432 | 0.180 |
Why?
|
| Ambulatory Care | 1 | 2021 | 58 | 0.180 |
Why?
|
| Body Mass Index | 3 | 2014 | 386 | 0.180 |
Why?
|
| Gestational Age | 3 | 2013 | 140 | 0.180 |
Why?
|
| Infertility | 1 | 2021 | 35 | 0.180 |
Why?
|
| Fetal Death | 2 | 2013 | 21 | 0.170 |
Why?
|
| Cohort Studies | 5 | 2015 | 859 | 0.170 |
Why?
|
| African Americans | 2 | 2020 | 350 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 66 | 0.170 |
Why?
|
| Biomedical Research | 2 | 2018 | 93 | 0.170 |
Why?
|
| Patient Care Management | 1 | 2019 | 10 | 0.170 |
Why?
|
| Withholding Treatment | 1 | 2019 | 20 | 0.170 |
Why?
|
| Survival Analysis | 2 | 2012 | 276 | 0.170 |
Why?
|
| Autoimmunity | 1 | 2020 | 153 | 0.160 |
Why?
|
| Breast Feeding | 2 | 2010 | 87 | 0.160 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 980 | 0.160 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 274 | 0.160 |
Why?
|
| Prenatal Diagnosis | 1 | 2018 | 17 | 0.160 |
Why?
|
| Heart Block | 1 | 2018 | 43 | 0.160 |
Why?
|
| B-Cell Activating Factor | 2 | 2020 | 31 | 0.150 |
Why?
|
| Decision Making | 1 | 2020 | 169 | 0.150 |
Why?
|
| Health Surveys | 2 | 2009 | 77 | 0.150 |
Why?
|
| Herpesvirus 4, Human | 1 | 2018 | 41 | 0.150 |
Why?
|
| Viral Proteins | 1 | 2018 | 62 | 0.150 |
Why?
|
| Interleukin-10 | 1 | 2018 | 68 | 0.150 |
Why?
|
| Menopause | 1 | 2018 | 28 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2016 | 75 | 0.150 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2017 | 7 | 0.150 |
Why?
|
| Luminescent Measurements | 1 | 2017 | 30 | 0.150 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2017 | 12 | 0.150 |
Why?
|
| Double-Blind Method | 3 | 2015 | 399 | 0.150 |
Why?
|
| Dermatomyositis | 1 | 2017 | 60 | 0.150 |
Why?
|
| Activities of Daily Living | 1 | 2018 | 100 | 0.140 |
Why?
|
| Linear Models | 2 | 2008 | 201 | 0.140 |
Why?
|
| Monocytes | 1 | 2018 | 132 | 0.140 |
Why?
|
| Neutrophils | 1 | 2018 | 177 | 0.140 |
Why?
|
| Inflammation | 3 | 2020 | 601 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 279 | 0.140 |
Why?
|
| Prednisone | 4 | 2014 | 51 | 0.140 |
Why?
|
| Placenta | 1 | 2017 | 74 | 0.140 |
Why?
|
| Sjogren's Syndrome | 1 | 2020 | 256 | 0.140 |
Why?
|
| Patient Compliance | 1 | 2017 | 75 | 0.140 |
Why?
|
| Proportional Hazards Models | 2 | 2008 | 213 | 0.140 |
Why?
|
| West Nile virus | 1 | 2016 | 20 | 0.140 |
Why?
|
| Papillomavirus Vaccines | 1 | 2017 | 53 | 0.130 |
Why?
|
| Guideline Adherence | 1 | 2017 | 91 | 0.130 |
Why?
|
| Osteoarthritis | 2 | 2007 | 35 | 0.130 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 56 | 0.130 |
Why?
|
| Quality of Life | 2 | 2018 | 463 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 68 | 0.130 |
Why?
|
| Smoking | 2 | 2012 | 466 | 0.130 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 121 | 0.130 |
Why?
|
| Pilot Projects | 3 | 2013 | 390 | 0.130 |
Why?
|
| Obstetric Labor, Premature | 2 | 2006 | 15 | 0.130 |
Why?
|
| Cesarean Section | 2 | 2006 | 55 | 0.120 |
Why?
|
| Hydroxychloroquine | 2 | 2013 | 19 | 0.120 |
Why?
|
| Kidney | 1 | 2016 | 275 | 0.120 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 482 | 0.120 |
Why?
|
| Interleukin-17 | 1 | 2015 | 51 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 190 | 0.120 |
Why?
|
| Fertility | 1 | 2015 | 58 | 0.120 |
Why?
|
| Transcription Factors | 1 | 2018 | 511 | 0.120 |
Why?
|
| Antigens, CD1d | 1 | 2014 | 45 | 0.120 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2014 | 10 | 0.120 |
Why?
|
| Oligopeptides | 1 | 2015 | 95 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 100 | 0.120 |
Why?
|
| Immunity | 1 | 2014 | 26 | 0.110 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 27 | 0.110 |
Why?
|
| Protein Array Analysis | 1 | 2013 | 18 | 0.110 |
Why?
|
| Signal Transduction | 1 | 2020 | 1344 | 0.110 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 26 | 0.110 |
Why?
|
| Contraindications | 1 | 2013 | 13 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2011 | 131 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2014 | 263 | 0.110 |
Why?
|
| Abortion, Spontaneous | 1 | 2012 | 15 | 0.100 |
Why?
|
| Autoantigens | 1 | 2013 | 212 | 0.100 |
Why?
|
| Family Characteristics | 1 | 2012 | 46 | 0.100 |
Why?
|
| Infertility, Female | 1 | 2012 | 42 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2011 | 18 | 0.100 |
Why?
|
| Mycophenolic Acid | 1 | 2011 | 16 | 0.100 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 144 | 0.100 |
Why?
|
| Odds Ratio | 2 | 2010 | 231 | 0.090 |
Why?
|
| Immunoconjugates | 1 | 2011 | 17 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2014 | 72 | 0.090 |
Why?
|
| Managed Care Programs | 1 | 2011 | 16 | 0.090 |
Why?
|
| Pregnancy, Unplanned | 1 | 2010 | 5 | 0.090 |
Why?
|
| Sex Factors | 2 | 2013 | 444 | 0.090 |
Why?
|
| Comorbidity | 1 | 2012 | 252 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2014 | 702 | 0.090 |
Why?
|
| Contraception | 1 | 2010 | 21 | 0.090 |
Why?
|
| Lymphoma | 1 | 2010 | 22 | 0.090 |
Why?
|
| Counseling | 1 | 2010 | 51 | 0.090 |
Why?
|
| Cytokines | 3 | 2020 | 439 | 0.090 |
Why?
|
| Medicare | 1 | 2011 | 118 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 62 | 0.090 |
Why?
|
| Osteoporosis | 1 | 2010 | 63 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2009 | 66 | 0.080 |
Why?
|
| Survival Rate | 1 | 2010 | 406 | 0.080 |
Why?
|
| Disease Progression | 3 | 2018 | 450 | 0.080 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2009 | 26 | 0.080 |
Why?
|
| Diagnostic Errors | 1 | 2009 | 33 | 0.080 |
Why?
|
| Prevalence | 2 | 2009 | 472 | 0.080 |
Why?
|
| Fibromyalgia | 1 | 2009 | 12 | 0.080 |
Why?
|
| DNA Viruses | 1 | 2008 | 3 | 0.080 |
Why?
|
| Hepatitis B, Chronic | 1 | 2008 | 6 | 0.080 |
Why?
|
| Polyomavirus Infections | 1 | 2008 | 6 | 0.080 |
Why?
|
| Hepacivirus | 1 | 2008 | 46 | 0.080 |
Why?
|
| Hepatitis C | 1 | 2008 | 38 | 0.080 |
Why?
|
| Immunoglobulin M | 1 | 2007 | 28 | 0.070 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2008 | 38 | 0.070 |
Why?
|
| Age Distribution | 1 | 2007 | 70 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2007 | 76 | 0.070 |
Why?
|
| Radiography | 1 | 2008 | 200 | 0.070 |
Why?
|
| Probability | 1 | 2007 | 75 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2014 | 586 | 0.070 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2007 | 13 | 0.070 |
Why?
|
| Pennsylvania | 1 | 2007 | 10 | 0.070 |
Why?
|
| International Cooperation | 1 | 2007 | 18 | 0.070 |
Why?
|
| Inpatients | 1 | 2007 | 56 | 0.070 |
Why?
|
| Anemia, Hemolytic | 1 | 2007 | 22 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 253 | 0.070 |
Why?
|
| Seizures | 1 | 2007 | 46 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 56 | 0.070 |
Why?
|
| Skin Diseases, Vascular | 1 | 2006 | 3 | 0.070 |
Why?
|
| Erythrocytes | 1 | 2007 | 83 | 0.070 |
Why?
|
| Musculoskeletal Diseases | 1 | 2006 | 5 | 0.070 |
Why?
|
| Epidemiologic Methods | 1 | 2006 | 21 | 0.070 |
Why?
|
| Plasma Exchange | 1 | 2007 | 103 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2007 | 228 | 0.070 |
Why?
|
| Vascular Diseases | 1 | 2007 | 67 | 0.070 |
Why?
|
| Fetal Membranes, Premature Rupture | 1 | 2006 | 5 | 0.070 |
Why?
|
| Age Factors | 1 | 2008 | 716 | 0.070 |
Why?
|
| Vaccines, Inactivated | 1 | 2005 | 4 | 0.070 |
Why?
|
| Phenotype | 2 | 2020 | 667 | 0.070 |
Why?
|
| Software | 1 | 2007 | 121 | 0.070 |
Why?
|
| Mycobacterium | 1 | 2005 | 3 | 0.070 |
Why?
|
| Immunotherapy, Active | 1 | 2005 | 6 | 0.070 |
Why?
|
| Thrombocytopenia | 1 | 2007 | 113 | 0.060 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2005 | 12 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2005 | 18 | 0.060 |
Why?
|
| Bacterial Vaccines | 1 | 2005 | 28 | 0.060 |
Why?
|
| Medical Records | 1 | 2005 | 49 | 0.060 |
Why?
|
| Coronary Artery Bypass | 1 | 2005 | 66 | 0.060 |
Why?
|
| Pyrazoles | 1 | 2005 | 62 | 0.060 |
Why?
|
| Coronary Angiography | 1 | 2005 | 149 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2005 | 69 | 0.060 |
Why?
|
| Prognosis | 2 | 2018 | 759 | 0.060 |
Why?
|
| Diabetes, Gestational | 1 | 2006 | 63 | 0.060 |
Why?
|
| Warfarin | 1 | 2005 | 94 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2005 | 66 | 0.060 |
Why?
|
| Risk | 1 | 2004 | 133 | 0.060 |
Why?
|
| Oklahoma | 2 | 2020 | 973 | 0.060 |
Why?
|
| Hemorrhage | 1 | 2005 | 259 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2005 | 293 | 0.050 |
Why?
|
| Etanercept | 1 | 2003 | 6 | 0.050 |
Why?
|
| Infliximab | 1 | 2003 | 6 | 0.050 |
Why?
|
| Isoxazoles | 1 | 2003 | 7 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2003 | 18 | 0.050 |
Why?
|
| Syndrome | 1 | 2003 | 78 | 0.050 |
Why?
|
| Data Collection | 1 | 2003 | 101 | 0.050 |
Why?
|
| Vitamin D | 2 | 2014 | 44 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2003 | 139 | 0.050 |
Why?
|
| Logistic Models | 2 | 2014 | 397 | 0.050 |
Why?
|
| Protective Factors | 1 | 2021 | 16 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2021 | 17 | 0.050 |
Why?
|
| Consensus | 1 | 2021 | 69 | 0.050 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2020 | 3 | 0.040 |
Why?
|
| Chemokine CXCL9 | 1 | 2020 | 3 | 0.040 |
Why?
|
| Chemokine CXCL13 | 1 | 2020 | 7 | 0.040 |
Why?
|
| Interleukin-1alpha | 1 | 2020 | 7 | 0.040 |
Why?
|
| Altruism | 1 | 2020 | 8 | 0.040 |
Why?
|
| Chemokine CXCL10 | 1 | 2020 | 22 | 0.040 |
Why?
|
| Culture | 1 | 2020 | 26 | 0.040 |
Why?
|
| Interferons | 1 | 2020 | 68 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 77 | 0.040 |
Why?
|
| Minority Groups | 1 | 2020 | 61 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 89 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 81 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2020 | 118 | 0.040 |
Why?
|
| Interleukins | 1 | 2020 | 108 | 0.040 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2018 | 14 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2020 | 172 | 0.040 |
Why?
|
| Pregnancy Trimesters | 1 | 2018 | 5 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 110 | 0.040 |
Why?
|
| Reproductive History | 1 | 2018 | 8 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2018 | 86 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 109 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2018 | 134 | 0.040 |
Why?
|
| Maternal Age | 1 | 2017 | 25 | 0.040 |
Why?
|
| Transcriptome | 1 | 2018 | 199 | 0.040 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2016 | 3 | 0.030 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2016 | 12 | 0.030 |
Why?
|
| West Nile Fever | 1 | 2016 | 15 | 0.030 |
Why?
|
| Genome, Viral | 1 | 2016 | 28 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2018 | 205 | 0.030 |
Why?
|
| Animals | 3 | 2015 | 9962 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2016 | 53 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2016 | 58 | 0.030 |
Why?
|
| Virus Replication | 1 | 2016 | 55 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 189 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2016 | 67 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 199 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 152 | 0.030 |
Why?
|
| Perinatal Care | 1 | 2015 | 4 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 2014 | 8 | 0.030 |
Why?
|
| CD40 Ligand | 1 | 2014 | 13 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 627 | 0.030 |
Why?
|
| Patient Safety | 1 | 2015 | 36 | 0.030 |
Why?
|
| Mice | 2 | 2015 | 4406 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2014 | 29 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2014 | 21 | 0.030 |
Why?
|
| Cell Separation | 1 | 2014 | 55 | 0.030 |
Why?
|
| Protein Binding | 1 | 2016 | 631 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2014 | 69 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2014 | 19 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2014 | 37 | 0.030 |
Why?
|
| Mycobacterium Infections | 1 | 2013 | 1 | 0.030 |
Why?
|
| Polyendocrinopathies, Autoimmune | 1 | 2013 | 1 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 2014 | 41 | 0.030 |
Why?
|
| Estrogens | 1 | 2014 | 56 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2016 | 970 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2015 | 560 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2014 | 114 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2013 | 113 | 0.030 |
Why?
|
| Fetal Distress | 1 | 2013 | 1 | 0.030 |
Why?
|
| Recurrence | 1 | 2014 | 316 | 0.030 |
Why?
|
| Siblings | 1 | 2013 | 23 | 0.030 |
Why?
|
| Congenital Abnormalities | 1 | 2013 | 16 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 408 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2014 | 395 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 747 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2011 | 10 | 0.020 |
Why?
|
| San Francisco | 1 | 2010 | 7 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2011 | 51 | 0.020 |
Why?
|
| Bone Density Conservation Agents | 1 | 2010 | 18 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2011 | 100 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 241 | 0.020 |
Why?
|
| Indians, North American | 1 | 2014 | 511 | 0.020 |
Why?
|
| Bone Density | 1 | 2010 | 99 | 0.020 |
Why?
|
| Calcium | 1 | 2010 | 231 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 508 | 0.020 |
Why?
|
| Fatigue | 1 | 2009 | 57 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2010 | 213 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2007 | 15 | 0.020 |
Why?
|
| RNA, Double-Stranded | 1 | 2007 | 15 | 0.020 |
Why?
|
| Complement C3 | 1 | 2007 | 21 | 0.020 |
Why?
|
| Adalimumab | 1 | 2007 | 3 | 0.020 |
Why?
|
| Hand | 1 | 2007 | 25 | 0.020 |
Why?
|
| Cartilage, Articular | 1 | 2007 | 43 | 0.020 |
Why?
|
| Forearm | 1 | 2006 | 36 | 0.020 |
Why?
|
| Abdomen | 1 | 2006 | 41 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2006 | 21 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 99 | 0.020 |
Why?
|
| Pain | 1 | 2009 | 252 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 43 | 0.020 |
Why?
|
| Injections, Intradermal | 1 | 2005 | 2 | 0.020 |
Why?
|
| Thrombomodulin | 1 | 2005 | 10 | 0.020 |
Why?
|
| Celecoxib | 1 | 2005 | 9 | 0.020 |
Why?
|
| Leg | 1 | 2006 | 131 | 0.020 |
Why?
|
| E-Selectin | 1 | 2005 | 27 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2005 | 25 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2005 | 77 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 203 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2007 | 771 | 0.010 |
Why?
|